12/19/2025 | Butantan Institute

https://butantan.gov.br/noticias/instituto-butantan-dara-inicio-a-entrega-de-13-milhao-de-doses-da-vacina-contra-a-dengue-ao-ministerio-da-saude 

The first 300 thousand doses will be delivered at the beginning of next week; Until the end of January 2026, more than a thousand doses will be available to the National Immunization Program (PNI)

The Butantan Institute, an organization linked to the Secretary of State for Health of São Paulo, will begin next week with the delivery of 1.3 million doses of the vaccine against dengue for the National Imunization Program (PNI) of the Ministry of Health. The first 300 thousand doses will be delivered starting next week and, until the end of January 2026, more than a thousand doses will be delivered. Butantan-DV is the first vaccine in the world to be used alone against dengue. The confirmation of the contract was carried out on this sixth fair (19) between the Butantan Institute and the Ministry of Health.

Delivery is being possible because, even before approval by the National Sanitary Surveillance Agency (Anvisa), the Butantan Institute had already begun, above all, the production of the immunizer in its industrial park. Além disso, Butantan formed an international partnership with the Chinese company WuXi to increase production and expand delivery in the second half of 2026.

"More an important milestone in this day of achievements of Brazilian science. With the formalization of the agreement between the Butantan Institute and the Ministry of Health, we will begin the delivery of two doses of the vaccine against dengue. As well, in January, it will be possible to begin placing the vaccine in the arms of two Brazilians," says the director of the Butantan Institute, Esper Kallas.

Butantan-DV was approved by Anvisa to be used by the Brazilian population from 12 to 59 years old. Public use, the immunizer showed 74.7% general effectiveness, 91.6% effectiveness against severe dengue and with alarm signals and 100% effectiveness against dengue hospitalizations.

In accordance with the strategy announced by the Ministry of Health, these first two deliveries at this time by the Butantan Institute will be destined for the Primary Care professionals, who operate in the Basic Health Units (UBSs) and in home visits. With the expansion of productive capacity, the ministry should extend vaccination to the general public, starting with adults aged 59 and gradually advancing until reaching the age of 15.

Other publics
The Butantan Institute aims to expand the age range of the vaccine both for the pediatric public and for those over 60 years of age. For this reason, you have received approval from Anvisa to validate the dengue vaccine in the population between 60 and 79 years old.

If the results of the investigation are not satisfactory, it will be possible to request the regulatory agency even from this group for the immunization recommendations. Also, more data should be collected to validate the possibilities even of children from 2 to 11 years old in the recommendations of the cow. The clinical studies carried out have proven that the vaccine is safe in this age group.